Companies › Bluefin Biomedicine
1 active drug program in 2 registered trials: 2 Phase 2; Immunology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BFB759 Human monoclonal antibody inhibiting multiple pro-inflammatory cytokines | – | Phase 2 | Atopic Dermatitis (AD); Hidradenitis Suppurativa (HS) | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07105488 | BFB759 | Phase 2 | Atopic Dermatitis (AD) | Immunology | Feb 2027 |
| NCT07287644 | BFB759 | Phase 2 | Hidradenitis Suppurativa (HS) | Immunology | Aug 2027 |
No annotated target.
–
Elixiron Immunotherapeutics (Hong Kong) SinoMab BioScience Aravax VivaTech International AltruBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.